NCT00478049View on ClinicalTrials.gov

Iressa as Second Line Therapy in Advanced NSCLC-Asia

PHASE3CompletedINTERVENTIONAL

Enrollment

163

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

May 31, 2007

Study Completion Date

February 28, 2009

Conditions

NSCLC

Interventions

DRUG

Gefitinib

250 mg oral tablet

DRUG

Docetaxel

intravenous infusion

Trial Locations (4)

Unknown

Research Site, Incheon

Research Site, Kyonggi-do

Research Site, Seoul

Research Site, Suwon

Sponsors

Lead Sponsor

All Listed Sponsors

lead

AstraZeneca

INDUSTRY